by Sermonix Pharmaceuticals | Jun 2, 2019 | News
CHICAGO—Findings suggest that lasofoxifene, in combination with CDK4/6 inhibitors like palbociclib, is a promising approach for the treatment of endocrine therapy resistant ER+ metastatic breast cancer patients (Abstract 1056). “Lasofoxifene is a legacy molecule...
by Sermonix Pharmaceuticals | May 28, 2019 | News
Designation allows for expedited development and review of lasofoxifene as a potential precision medicine treatment for women who have estrogen receptor-positive (ER+) metastatic breast cancer with an ESR1 mutation COLUMBUS, Ohio, May 28, 2019 (GLOBE NEWSWIRE) —...
by Sermonix Pharmaceuticals | May 7, 2019 | News
Biopharmaceutical company studied combination of lasofoxifene and CDK4/6 inhibitor palbociclib versus fulvestrant and palbociclib in animal models. COLUMBUS, Ohio (May 7, 2019) – Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the...
by Sermonix Pharmaceuticals | Apr 23, 2019 | News
Richard U. DeSchutter, Michael A. Friedman and Stephen Rubino bring decades of diverse C-level experience to biopharmaceutical company conducting a Phase 2 clinical trial for the precision medicine treatment of metastatic breast cancer COLUMBUS, Ohio (April 23, 2019)...
by Sermonix Pharmaceuticals | Mar 11, 2019 | News
COLUMBUS, Ohio, March 11, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that founder and Chief Executive Officer...
by Sermonix Pharmaceuticals | Mar 4, 2019 | News
Biopharmaceutical company collaborated with Ben May Department for Cancer Research at University of Chicago to study efficacy of lasofoxifene COLUMBUS, Ohio, March 04, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company...
Recent Comments